UB Paderborn / Katalog / Suche / in CDI

1 – 15 von 15

Sortiert nach

ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors—A systematic review and meta-analysis of real world data

Lung cancer (Amsterdam, Netherlands), 2020-07, Vol.145, p.95-104

2020

Volltextzugriff (PDF)

Immortal Time Bias Question in the Association Between Toxicity and Outcome of Immune Checkpoint Inhibitors

Journal of clinical oncology, 2020-01, Vol.38 (1), p.105-106

2020

Volltextzugriff (PDF)

Tumour burden and efficacy of immune-checkpoint inhibitors

Nature reviews. Clinical oncology, 2022-02, Vol.19 (2), p.75-90

2022

Volltextzugriff (PDF)

Overcoming Primary Resistance to PD-1 Inhibitor With Anti–PD-L1 Agent in Squamous-Cell NSCLC: Case Report

Clinical lung cancer, 2020-03, Vol.21 (2), p.e45-e48

2020

Volltextzugriff (PDF)

Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non–small cell lung cancer treated with first-line pembrolizumab

European journal of cancer (1990), 2021-06, Vol.150, p.99-107

2021

Volltextzugriff (PDF)

PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non–small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors

Clinical lung cancer, 2021-09, Vol.22 (5), p.423-431

2021

Volltextzugriff (PDF)

Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients – A single centre experience

Lung cancer (Amsterdam, Netherlands), 2020-11, Vol.149, p.5-9

2020

Volltextzugriff (PDF)

The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma-Letter

Clinical cancer research, 2020-01, Vol.26 (2), p.518-519

2020

Volltextzugriff (PDF)

CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors

Therapeutic advances in medical oncology, 2020, Vol.12, p.1758835920952994-1758835920952994

2020

Volltextzugriff (PDF)

Clinical and demographic factors associated to the place of death in advanced cancer patients assisted at home in Italy

Progress in palliative care, 2015-04, Vol.23 (2), p.61-67

2015

Volltextzugriff (PDF)

The ‘surprise’ question in advanced cancer patients: A prospective study among general practitioners

Palliative medicine, 2014-07, Vol.28 (7), p.959-964

2014

Volltextzugriff (PDF)

Monitoring tumor growth rate to predict immune checkpoint inhibitors’ treatment outcome in advanced NSCLC

Therapeutic advances in medical oncology, 2022, Vol.14, p.17588359211058391-17588359211058391

2022

Volltextzugriff (PDF)

Immortal time bias in the association between toxicity and response for immune checkpoint inhibitors: A systematic review and meta-analysis

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e15080-e15080

2020

Volltextzugriff (PDF)

Overcoming Primary Resistance to PD-1 Inhibitor With Anti-PD-L1 Agent in Squamous-Cell NSCLC: Case Report

Clinical lung cancer, 2020, Vol.21 (2), p.e45-e48

2020

Volltextzugriff (PDF)

1 – 15 von 15

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(14)
Mit Volltextzugriff
(13)

Publikationsform

Artikel
(14)
Berichte
(1)

Sprache

Englisch
(15)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(12)
Science & Technology
(12)
Oncology
(10)
Humans
(5)
Immunotherapy
(5)
Lung Cancer
(5)
Prognosis
(5)
Chemotherapy
(4)
Immune Checkpoint Inhibitors
(4)
Immune Checkpoint Inhibitors - Therapeutic Use
(4)
Tumors
(4)
Aged
(3)
Cancer
(3)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(3)
Carcinoma, Non-Small-Cell Lung - Pathology
(3)
Computed Tomography
(3)
Female
(3)
Non-Small Cell Lung Carcinoma
(3)
Nsclc
(3)
Patients
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors—A systematic review and meta-analysis of real world data

Immortal Time Bias Question in the Association Between Toxicity and Outcome of Immune Checkpoint Inhibitors

Tumour burden and efficacy of immune-checkpoint inhibitors

Overcoming Primary Resistance to PD-1 Inhibitor With Anti–PD-L1 Agent in Squamous-Cell NSCLC: Case Report

Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations

Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non–small cell lung cancer treated with first-line pembrolizumab

PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non–small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors

Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients – A single centre experience

The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma-Letter

CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors

Clinical and demographic factors associated to the place of death in advanced cancer patients assisted at home in Italy

The ‘surprise’ question in advanced cancer patients: A prospective study among general practitioners

Monitoring tumor growth rate to predict immune checkpoint inhibitors’ treatment outcome in advanced NSCLC

Immortal time bias in the association between toxicity and response for immune checkpoint inhibitors: A systematic review and meta-analysis

Overcoming Primary Resistance to PD-1 Inhibitor With Anti-PD-L1 Agent in Squamous-Cell NSCLC: Case Report

Suchergebnisse filtern